Principal Financial Group Inc. Acquires 25,031 Shares of ICU Medical, Inc. (NASDAQ:ICUI)

Principal Financial Group Inc. lifted its holdings in shares of ICU Medical, Inc. (NASDAQ:ICUI) by 24.6% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 126,937 shares of the medical instruments supplier’s stock after buying an additional 25,031 shares during the quarter. Principal Financial Group Inc. owned about 0.52% of ICU Medical worth $23,130,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of the business. Hexagon Capital Partners LLC grew its holdings in ICU Medical by 162.7% during the 3rd quarter. Hexagon Capital Partners LLC now owns 197 shares of the medical instruments supplier’s stock valued at $36,000 after buying an additional 122 shares in the last quarter. Allworth Financial LP grew its stake in ICU Medical by 100.0% during the third quarter. Allworth Financial LP now owns 200 shares of the medical instruments supplier’s stock valued at $36,000 after acquiring an additional 100 shares in the last quarter. Innealta Capital LLC bought a new stake in ICU Medical during the 2nd quarter worth approximately $32,000. Motco purchased a new stake in ICU Medical in the 1st quarter worth approximately $29,000. Finally, EntryPoint Capital LLC lifted its stake in ICU Medical by 731.5% in the 1st quarter. EntryPoint Capital LLC now owns 449 shares of the medical instruments supplier’s stock worth $48,000 after purchasing an additional 395 shares in the last quarter. 96.10% of the stock is owned by institutional investors.

Insider Activity

In other ICU Medical news, CEO Vivek Jain sold 12,000 shares of the business’s stock in a transaction that occurred on Friday, August 16th. The stock was sold at an average price of $156.04, for a total value of $1,872,480.00. Following the completion of the sale, the chief executive officer now owns 104,593 shares in the company, valued at approximately $16,320,691.72. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other news, VP Daniel Woolson sold 2,502 shares of ICU Medical stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $163.22, for a total value of $408,376.44. Following the sale, the vice president now directly owns 13,107 shares in the company, valued at approximately $2,139,324.54. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Vivek Jain sold 12,000 shares of the company’s stock in a transaction that occurred on Friday, August 16th. The shares were sold at an average price of $156.04, for a total value of $1,872,480.00. Following the transaction, the chief executive officer now owns 104,593 shares of the company’s stock, valued at approximately $16,320,691.72. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 50,502 shares of company stock valued at $8,445,976. 6.70% of the stock is currently owned by insiders.

ICU Medical Price Performance

ICUI opened at $174.81 on Thursday. The stock has a market capitalization of $4.27 billion, a P/E ratio of -38.25 and a beta of 0.66. The company has a current ratio of 2.41, a quick ratio of 1.08 and a debt-to-equity ratio of 0.76. ICU Medical, Inc. has a 12-month low of $82.82 and a 12-month high of $196.26. The stock has a 50-day moving average price of $176.11 and a 200-day moving average price of $141.98.

ICU Medical (NASDAQ:ICUI) last announced its quarterly earnings data on Tuesday, November 12th. The medical instruments supplier reported $1.23 earnings per share for the quarter, topping analysts’ consensus estimates of $0.88 by $0.35. ICU Medical had a negative net margin of 4.74% and a positive return on equity of 5.04%. The firm had revenue of $580.07 million during the quarter, compared to analyst estimates of $574.77 million. Equities analysts predict that ICU Medical, Inc. will post 3.81 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the stock. Raymond James upped their price target on shares of ICU Medical from $158.00 to $190.00 and gave the stock an “outperform” rating in a report on Thursday, September 12th. StockNews.com lowered ICU Medical from a “buy” rating to a “hold” rating in a research note on Tuesday. KeyCorp lifted their price target on ICU Medical from $198.00 to $209.00 and gave the company an “overweight” rating in a research report on Wednesday. Needham & Company LLC restated a “hold” rating on shares of ICU Medical in a research report on Wednesday. Finally, Jefferies Financial Group started coverage on shares of ICU Medical in a research note on Monday, October 14th. They issued a “hold” rating and a $183.00 target price on the stock. Three analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to MarketBeat, ICU Medical currently has an average rating of “Moderate Buy” and an average target price of $173.00.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.